Thermo Fisher Scientific is trading higher following the August 25 announcement of its new Orbitrap Isora and Isora Pro mass spectrometers, which expand the company's capabilities in isotope ratio analysis. While the stock has seen significant momentum with a 30.6% gain over the past year, recent analysis has questioned its valuation, suggesting a lower intrinsic value based on discounted cash flow models. The company's performance remains largely decoupled from its peers in the diagnostics and research sector, where movements have been mixed, ranging from a 1.0% gain in West Pharmaceutical Services to a 2.1% decline in AMN Healthcare Services.